Managing HIV disease after Delta: Questions remain about how to manage patients already on nucleoside monotherapy

British Medical Journal

Volumn 312, Issue 7030, 1996, Pages 521-522

  Pinching, Anthony J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PRACTICE; DISEASE COURSE; DRUG COST; DRUG RESEARCH; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0030022953     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volderding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;371:185-91.
2. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al for the AIDS Clinical Trials Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112: 727-37.
3. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP, for the NIAID State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Anti-retroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
4. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al for the AIDS Clinical Trials Group of the NIAID. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990;322:941-9.
5. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343: 871-81.